Biology of Blood and Marrow Transplantation
Volume 15, Issue 8 , Pages 963-970 , August 2009

Strategies to Improve Long-Term Outcome in Stage IIIB Inflammatory Breast Cancer: Multimodality Treatment Including Dose-Intensive Induction and High-Dose Chemotherapy

  • Claude Sportès

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationCorrespondence and reprint requests: Claude Sportès, MD, Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center drive, Room 43142, Bethesda, MD 20892-1203.
    • ,
  • Seth M. Steinberg

      Affiliations

    • Biostatistics & Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • David J. Liewehr

      Affiliations

    • Biostatistics & Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Juan Gea-Banacloche

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • David N. Danforth

      Affiliations

    • Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Daniele N. Avila

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Kelly E. Bryant

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Michael C. Krumlauf

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Daniel H. Fowler

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Steven Pavletic

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Nancy M. Hardy

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Michael R. Bishop

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Ronald E. Gress

      Affiliations

    • Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Received 18 February 2009 ,Accepted 25 April 2009.

References 

  1. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer. 1974;33:1045–1047
  2. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452–461
  3. Gurney H, Harnett P, Kefford R, et al. Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. Aust N Z J Med. 1998;28:400–402
  4. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321–329
  5. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067–4074
  6. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–975
  7. De Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery?. Ann Oncol. 2000;11:1147–1153
  8. Brooks HL, Mandava N, Pizzi WF, et al. Inflammatory breast carcinoma: a community hospital experience. J Am Coll Surg. 1998;186:622–629
  9. Tokuda Y, Tajima T, Narabayashi M, et al. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci. 2008;99:145–151
  10. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366:1935–1944
  11. Roche H, Viens P, Biron P, et al. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control. 2003;10:42–47
  12. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7–16
  13. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17–26
  14. Moore HC, Green SJ, Gralow JR, et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007;25:1677–1682
  15. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92:225–233
  16. Hanrahan EO, Broglio K, Frye D, et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer. 2006;106:2327–2336
  17. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23:2191–2200
  18. Coombes RC, Howell A, Emson M, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with 4 or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol. 2005;16:726–734
  19. Leonard RC, Lind M, Twelves C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004;96:1076–1083
  20. Zander AR, Kroger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;22:2273–2283
  21. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384–1391
  22. Gianni AM, Bonadonna G, Michelangelo G, et al. Updated 12-year results of a randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than 3 positive nodes (LN+). ASCO Meet Abstr. 2007;25:549
  23. Basser R, O'Neill G, Martinelli G, et al. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): first results from the IBCSG Trial 15-95. Proc Am Soc Clin Oncol. 2003;22:6
  24. Farquhar CM, Marjoribanks J, Lethaby A, et al. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev. 2007;33:325–337
  25. Ueno NT, Berry DA, Johnson MM, et al. High-dose chemotherapy with a stem cell support-versus-standard dose chemotherapy: meta-analysis of individual patient data from 15 randomised breast cancer trial. Biol Blood Marrow Tranplant. 2008;14:91
  26. Rosti G, Ferrante P, Ledermann J, et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol/Hematol. 2002;41:129–140
  27. Sportes C, McCarthy NJ, Hakim F, et al. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol Blood Marrow Transplant. 2005;11:472–483
  28. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775–1782
  29. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769–777
  30. Viens P, Penault-Llorca F, Jacquemier J, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant. 1998;21:249–254
  31. Adkins D, Brown R, Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol. 1999;17:2006–2014
  32. Arun B, Slack R, Gehan E, et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999;85:93–99
  33. Schwartzberg L, Weaver C, Lewkow L, et al. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant. 1999;24:981–987
  34. Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999;81:449–456
  35. Macquart-Moulin G, Viens P, Palangie T, et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?. [In Process Citation] J Clin Oncol. 2000;18:754
  36. Viens P, Maraninchi D. High-dose chemotherapy in advanced breast cancer. Crit Rev Oncol Hematol. 2002;41:141–149
  37. Cagnoni PJ, Nieto Y, Shpall EJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998;16:1661–1668
  38. Nieto Y, Nawaz S, Shpall EJ, et al. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res. 2004;10:2609–2617
  39. Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998;16:1000–1007
  40. Dazzi C, Cariello A, Rosti G, et al. Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica. 2001;86:523–529
  41. Tolcher AW, Cowan KH, Noone MH, et al. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol. 1996;14:95–102

 Financial disclosure: See acknowledgments on page 969.

PII: S1083-8791(09)00215-8

doi: 10.1016/j.bbmt.2009.04.018

Biology of Blood and Marrow Transplantation
Volume 15, Issue 8 , Pages 963-970 , August 2009

Article Tools

* Image Usage & Resolution